Summary: New neurogenetics research shows that the APOE ε4 genetic variant—best known for increasing Alzheimer’s disease risk—also shapes how pathology spreads in amyotrophic lateral sclerosis (ALS). The study demonstrates that ALS is not a single uniform disorder but comprises biologically distinct subtypes, and that a patient’s APOE genotype strongly influences whether disease pathology remains localized or becomes widespread and cognitive.
By analyzing 145 autopsy-confirmed sporadic ALS cases, investigators found that people who carry APOE ε4 are far more likely to develop a broad, brain-wide form of ALS in which toxic protein inclusions spread beyond motor regions and contribute to cognitive decline and dementia.
Key Facts
- ALS and its protein signature: ALS is a progressive neurodegenerative disease that destroys motor neurons responsible for movement, speech, swallowing, and breathing. A central pathological hallmark in most sporadic ALS cases is the abnormal accumulation of phosphorylated TDP-43 (pTDP-43) in neural tissue.
- Pathological subtypes: The anatomical distribution of pTDP-43 varies between patients. In Type 1 ALS, pTDP-43 remains largely confined to motor-related regions. In Type 2 ALS, pTDP-43 spreads extensively into the frontal lobes, temporal lobes, and hippocampus, contributing to cognitive and behavioral impairments.
- APOE ε4 as a modifier: In this cohort, 65.5% of APOE ε4 carriers exhibited the widespread Type 2 pathology, compared with 39.7% of non-carriers, indicating a strong association between APOE ε4 and the brain-wide ALS subtype.
- Independent mechanism: Advanced statistical modeling and machine learning indicate that the effect of APOE ε4 on pTDP-43 spread operates independently from classic Alzheimer’s-related changes (amyloid-β and tau), pointing to a distinct biological pathway.
- Implications for personalized care: Incorporating APOE genotype into clinical assessment could help predict cognitive risk, guide timely cognitive testing, inform communication support planning, and shape decisions about respiratory care and other long-term interventions.
Source: Niigata University
Research from the Brain Research Institute at Niigata University finds APOE ε4 influences pathological spread in ALS
The study was published in Acta Neuropathologica.
ALS most commonly involves abnormal inclusions of phosphorylated TDP-43 (pTDP-43) inside neurons and glia. While some patients develop pathology that remains focused on motor circuits, others show extensive cortical involvement that affects memory, language, and behavior. Those with broader pTDP-43 spread face a higher risk of cognitive impairment and dementia, but the reasons for this variability have been unclear.
Because APOE ε4 is established as a major genetic risk factor for Alzheimer’s disease and has been linked to altered protein spreading in other neurodegenerative disorders, the research team investigated whether APOE ε4 also affects the distribution of TDP-43 pathology in ALS. They combined neuropathological staging with genetic data, including exome sequencing, in a well-characterized series of autopsy-confirmed sporadic ALS cases.
Cases were categorized into two neuropathological subtypes: type 1, where TDP-43 pathology is mainly limited to motor regions, and type 2, where pathology extends into frontotemporal cortex and the hippocampus. Statistical analyses compared the prevalence of these subtypes in APOE ε4 carriers versus non-carriers and tested whether the association was independent of Alzheimer’s-related amyloid-β and tau pathology.
The investigators found a notably higher proportion of the widespread Type 2 pathology among APOE ε4 carriers. Machine learning methods and Bayesian structural equation modeling supported a direct relationship between APOE ε4 and the Type 2 TDP-43 pattern that did not depend on coexisting amyloid-β or tau changes. Rare variants in known ALS genes did not show a clear effect on pathological subtype in this cohort.
According to the authors, these results suggest APOE ε4 modifies the anatomical distribution of TDP-43 pathology through mechanisms distinct from the classic Alzheimer’s cascade. The study reframes ALS as a group of biologically different subtypes influenced by genetic background, rather than a single uniform disease.
Clinically, determining APOE genotype at or near the time of ALS diagnosis could help healthcare teams anticipate which patients face a higher likelihood of cognitive decline, prioritize early neuropsychological evaluations, tailor communication strategies, and plan the timing of supportive interventions such as ventilatory support with greater foresight.
The authors note that further research is needed to confirm these findings in independent cohorts and to uncover the molecular pathways by which APOE ε4 promotes broader TDP-43 spread. Nevertheless, this work points toward more personalized, subtype-focused approaches to ALS research and care.
Key Questions Answered:
A: No. Carrying APOE ε4 is a genetic risk factor that can influence how pathological proteins accumulate and spread if a neurodegenerative disease arises, but it does not guarantee that a person will develop Alzheimer’s disease or ALS. The new study indicates that among people who already develop ALS, APOE ε4 increases the likelihood that the disease will adopt a widespread, cognitive-involving subtype.
A: APOE ε4 appears to influence protein dynamics across multiple neurodegenerative diseases. In this study, APOE ε4 was associated with increased spread of pTDP-43 in ALS through a mechanism that seems independent of amyloid-β and tau, suggesting the variant can alter pathological processes beyond those classically linked to Alzheimer’s disease.
A: This finding is a step toward more personalized care. Routine APOE genotyping at diagnosis could help clinicians identify patients at higher risk for cognitive decline and proactively plan cognitive monitoring, communication support, and timing of interventions. However, wider clinical adoption will depend on replication of results and development of subtype-specific management guidelines.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The cited journal paper was reviewed in full by the editorial team.
- Additional explanatory context was added by staff to clarify clinical implications.
About this genetics and ALS research news
Author: Yuya Hatano
Source: Niigata University
Contact: Yuya Hatano – Niigata University
Image credit: Neuroscience News
Original Research: Open access. “APOE ε4 influences the widespread TDP-43 pathological subtype in sporadic amyotrophic lateral sclerosis” by Yuya Hatano, Asa Nakahara, Mari Tada, Akiyoshi Kakita, Osamu Onodera & Tomohiko Ishihara. DOI: 10.1007/s00401-026-03029-y
Abstract
APOE ε4 influences the widespread TDP-43 pathological subtype in sporadic amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis is a fatal neurodegenerative disorder in which most sporadic cases display pathological inclusions of TAR DNA-binding protein 43 (TDP-43). The anatomical distribution of TDP-43 differs among patients, and the factors driving this heterogeneity have been unclear.
Because apolipoprotein E (APOE) ε4 is known to influence protein propagation in several neurodegenerative diseases, the authors evaluated whether APOE ε4 affects the spread of TDP-43 in ALS. They examined 145 autopsy-confirmed sporadic ALS cases, classifying TDP-43 pathology into two subtypes: type 1, largely restricted to motor regions, and type 2, marked by widespread cortical involvement. APOE genotypes and rare variants in ALS-associated genes were determined by exome sequencing, and amyloid-β and tau pathologies were assessed using established neuropathological staging systems.
Using structural equation modeling and an unbiased random forest approach, the study found that APOE ε4 carriers more frequently exhibited the widespread Type 2 pathology. Bayesian modeling indicated a direct association between APOE ε4 and the Type 2 TDP-43 pattern that was independent of amyloid-β and tau, while also reproducing the known links between APOE ε4 and Alzheimer’s pathology. Rare variants in ALS-related genes did not clearly influence TDP-43 subtype distribution.
These results indicate that APOE ε4 modifies the anatomical distribution of TDP-43 pathology in sporadic ALS through mechanisms separate from classical Alzheimer’s disease processes. Incorporating APOE genotype into ALS stratification could inform biologically grounded, subtype-specific therapeutic strategies.